Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine

Open Access 05-04-2024 | Hypoparathyroidism | Review

Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review

Authors: Matthias Büttner, Susanne Singer, Katherine Taylor

Published in: Endocrine

Login to get access

Abstract

Purpose

Hypoparathyroidism is defined by hypocalcemia with inappropriately normal or low parathyroid hormone levels. The current standard treatment consists of lifelong calcium and/ or vitamin D supplementation. Even while on stable treatment regimens, hypoparathyroid patients might still suffer from symptoms that can negatively impact their quality of life.

Methods

A systematic literature review to identify the current knowledge regarding quality of life in patients with hypoparathyroidism receiving standard treatment was performed on November 1st, 2023. PubMed as well as Web of Science were searched. The systematic review is registered in PROSPERO (#CRD42023470924).

Results

After removal of duplicates, 398 studies remained for title and abstract screening, after which 30 were included for full-text screening. After exclusion of seven studies with five studies lacking a control population, one using a non-validated questionnaire, and one being a subsample of the larger included study, 23 studies were included in this systematic review. The majority of the included studies used a guideline-conform definition of hypoparathyroidism, and the SF-36 was the most often applied tool. Almost all studies (87%) reported statistically significantly lower scores in at least one quality of life domain compared to a norm population or controls.

Conclusion

Patients with hypoparathyroidism receiving standard treatment report impairments in quality of life. The reasons for these impairments are probably multifaceted, making regular monitoring and the inclusion of various professionals necessary.
Literature
1.
M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke, L. Rejnmark, D.M. Mitchell, T.J. Vokes, K.K. Winer, D.M. Shoback, Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017)PubMedCrossRef
2.
Shoback D Clinical practice, Hypoparathyroidism. N. Engl. J. Med 359(4), 391–403 (2008)CrossRef
3.
D.M. Shoback, J.P. Bilezikian, A.G. Costa, D. Dempster, H. Dralle, A.A. Khan, M. Peacock, M. Raffaelli, B.C. Silva, R.V. Thakker, T. Vokes, R. Bouillon, Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J. Clin. Endocrinol. Metab. 101(6), 2300–2312 (2016)PubMedCrossRef
4.
O. Edafe, S.P. Balasubramanian, Incidence, prevalence and risk factors for post-surgical hypocalcaemia and hypoparathyroidism. Gland Surg. 6(Suppl 1), S59–S68 (2017)PubMedPubMedCentralCrossRef
5.
M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang, C. Fossum, K.J. Fougner, S.E. Holte, K. Lima, R.B. Moe, A.G. Myhre, E.H. Kemp, B.G. Nedrebo, J. Svartberg, E.S. Husebye, Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101(8), 3045–3053 (2016)PubMedPubMedCentralCrossRef
6.
C.G. Watson, D.L. Steed, A.G. Robinson, L.J. Deftos, The role of calcitonin and parathyroid hormone in the pathogenesis of post-thyroidectomy hypocalcemia. Metabolism 30(6), 588–589 (1981)PubMedCrossRef
7.
L. Cianferotti, S. Parri, G. Gronchi, G. Marcucci, C. Cipriani, J. Pepe, M. Raglianti, S. Minisola, M.L. Brandi, Prevalence of chronic hypoparathyroidism in a Mediterranean region as estimated by the analysis of anonymous healthcare database. Calcif. Tissue Int 103(2), 144–150 (2018)PubMedCrossRef
8.
C. Cipriani, J. Pepe, F. Biamonte, R. Manai, P. Biondi, L. Nieddu, L. Cianferotti, M.L. Brandi, S. Minisola, The epidemiology of hypoparathyroidism in Italy: an 8-year register-based study. Calcif. Tissue Int. 100(3), 278–285 (2017)PubMedCrossRef
9.
B.L. Clarke, E.M. Brown, M.T. Collins, H. Juppner, P. Lakatos, M.A. Levine, M.M. Mannstadt, J.P. Bilezikian, A.F. Romanischen, R.V. Thakker, Epidemiology and Diagnosis of Hypoparathyroidism. J. Clin. Endocrinol. Metab. 101(6), 2284–2299 (2016)PubMedPubMedCentralCrossRef
10.
L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J. Bone Min. Res. 28(11), 2277–2285 (2013)CrossRef
11.
L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, The epidemiology of nonsurgical hypoparathyroidism in Denmark: a Nationwide case finding study. J. Bone Min. Res. 30(9), 1738–1744 (2015)CrossRef
12.
T. Vadiveloo, P.T. Donnan, G.P. Leese, A population-based study of the epidemiology of chronic hypoparathyroidism. J. Bone Min. Res. 33(3), 478–485 (2018)CrossRef
13.
J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen, O.M. Dekkers, European society of E European Society of Endocrinology Clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173(2), G1–G20 (2015)PubMedCrossRef
14.
M. Buttner, D. Krogh, H. Siggelkow, S. Singer, Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey. Endocrine 82(2), 419–426 (2023)PubMedPubMedCentralCrossRef
15.
N. Hadker, J. Egan, J. Sanders, H. Lagast, B.L. Clarke, Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr. Pract. 20(7), 671–679 (2014)PubMedCrossRef
16.
L.A. Orloff, S.M. Wiseman, V.J. Bernet, T.J. Fahey 3rd, A.R. Shaha, M.L. Shindo, S.K. Snyder, B.C. Stack Jr, J.B. Sunwoo, M.B. Wang, American Thyroid Association Statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid 28(7), 830–841 (2018)PubMedCrossRef
17.
A.A. Khan, M.R. Rubin, P. Schwarz, T. Vokes, D.M. Shoback, C. Gagnon, A. Palermo, C. Marcocci, B.L. Clarke, L.G. Abbott, L.C. Hofbauer, L. Kohlmeier, S. Pihl, X. An, W.F. Eng, A.R. Smith, J. Ukena, C.T. Sibley, A.D. Shu, L. Rejnmark, Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J. Bone Min. Res. 38(1), 14–25 (2023)CrossRef
18.
A. Santonati, A. Palermo, E. Maddaloni, D. Bosco, A. Spada, F. Grimaldi, B. Raggiunti, R. Volpe, S. Manfrini, F. Vescini, A.M.E.G. Hypoparathyroidism, PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J. Clin. Endocrinol. Metab. 100(9), 3590–3597 (2015)PubMedCrossRef
19.
G. Tabacco, Y.D. Tay, N.E. Cusano, J. Williams, B. Omeragic, R. Majeed, M.G. Almonte, M.R. Rubin, J.P. Bilezikian, Quality of life in hypoparathyroidism improves with rhPTH(1-84) throughout 8 years of therapy. J. Clin. Endocrinol. Metab. 104(7), 2748–2756 (2019)PubMedPubMedCentralCrossRef
20.
T.J. Vokes, M. Mannstadt, M.A. Levine, B.L. Clarke, P. Lakatos, K. Chen, R. Piccolo, A. Krasner, D.M. Shoback, J.P. Bilezikian, Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 103(2), 722–731 (2018)PubMedCrossRef
21.
K.K. Winer, C.W. Ko, J.C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L.H. Gerber, C. McGarvey, G.B. Cutler Jr, Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88(9), 4214–4220 (2003)PubMedCrossRef
22.
M. Buttner, T.J. Musholt, S. Singer, Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58(1), 14–20 (2017)PubMedCrossRef
23.
M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas]. Rev. Panam. Salud Publica 46, e112 (2022)PubMedPubMedCentral
24.
25.
R. Herzog, M.J. Alvarez-Pasquin, C. Diaz, J.L. Del Barrio, J.M. Estrada, A. Gil, Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 13, 154 (2013)PubMedPubMedCentralCrossRef
26.
N.E. Cusano, M.R. Rubin, D.J. McMahon, D. Irani, L. Anderson, E. Levy, J.P. Bilezikian, PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J. Clin. Endocrinol. Metab. 99(10), 3694–3699 (2014)PubMedPubMedCentralCrossRef
27.
A.A. Khan, L. Rejnmark, M. Rubin, P. Schwarz, T. Vokes, B. Clarke, I. Ahmed, L. Hofbauer, C. Marcocci, U. Pagotto, A. Palermo, E. Eriksen, M. Brod, D. Markova, A. Smith, S. Pihl, S. Mourya, D.B. Karpf, A.D. Shu, PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J. Clin. Endocrinol. Metab. 107(1), e372–e385 (2022)PubMedCrossRef
28.
K.L. Roszko, T.Y. Hu, L.C. Guthrie, B.A. Brillante, M. Smith, M.T. Collins, R.I. Gafni, PTH 1-34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J. Bone Min. Res. 37(1), 68–77 (2022)CrossRef
29.
T. Sikjaer, L. Rolighed, A. Hess, A. Fuglsang-Frederiksen, L. Mosekilde, L. Rejnmark, Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos. Int 25(6), 1717–1726 (2014)PubMedCrossRef
30.
L. Underbjerg, T. Sikjaer, L. Rejnmark, Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin. Endocrinol. (Oxf.) 88(6), 838–847 (2018)PubMedCrossRef
31.
D. Wilde, L. Wilken, B. Stamm, C. Heppner, A. Leha, M. Blaschke, C. Herrmann-Lingen, H. Siggelkow, Quantification of symptom load by a disease-specific questionnaire HPQ 28 and analysis of associated biochemical parameters in patients with postsurgical hypoparathyroidism. JBMR 4(7), e10368 (2020)
32.
W. Arlt, C. Fremerey, F. Callies, M. Reincke, P. Schneider, W. Timmermann, B. Allolio, Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146(2), 215–222 (2002)PubMedCrossRef
33.
A.J. Arneiro, B.C.C. Duarte, R.M. Kulchetscki, V.B.S. Cury, M.P. Lopes, B.S. Kliemann, I.B. Bini, M. Assad, G.L.K. Biagini, V.Z.C. Borba, C.A. Moreira, Self-report of psychological symptoms in hypoparathyroidism patients on conventional therapy. Arch. Endocrinol. Metab. 62(3), 319–324 (2018)PubMedPubMedCentral
34.
M. Buttner, L.D. Locati, M. Pinto, C. Araujo, I.M. Tomaszewska, N. Kiyota, E. Vidhubala, C. Brannan, E. Hammerlid, O. Husson, D. Salem, G. Ioannidis, E. Gamper, J.I. Arraras, G. Andry, J. Inhestern, J. Theurer, K. Taylor, S. Singer, Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer. J. Clin. Endocrinol. Metab. 105(12), dgaa597 (2020)PubMedCrossRef
35.
F. Cherchir, I. Oueslati, M. Yazidi, F. Chaker, M. Chihaoui, Assessment of quality of life in patients with permanent hypoparathyroidism receiving conventional treatment. J. Diabetes Metab. Disord. 22(2), 1617–1623 (2023)PubMedCrossRef
36.
S. Frey, L. Figueres, F. Pattou, M. Le Bras, C. Caillard, M. Mathonnet, A. Hamy, L. Brunaud, J.C. Lifante, C. Tresallet, F. Sebag, F. Menegaux, C. Blanchard, M. Leroy, E. Mirallie, Qol-Hypopara Study G impact of permanent post-thyroidectomy hypoparathyroidism on self-evaluation of quality of life and voice: results from the National QoL-Hypopara study. Ann. Surg. 274(5), 851–858 (2021)PubMedCrossRef
37.
S. Hepsen, P. Akhanli, D. Sakiz, M.E. Sencar, B. Ucan, I.O. Unsal, E. Cakal, M. Ozbek, The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism. Arch. Osteoporos. 15(1), 75 (2020)PubMedCrossRef
38.
S.L. Hillary, J.E. Chooi, J. Wadsley, J.D. Newell-Price, N.J. Brown, S.P. Balasubramanian, Quality of life in post-surgical hypoparathyroidism (PoSH) in thyroid and parathyroid surgery. World J. Surg. 46(12), 3025–3033 (2022)PubMedPubMedCentralCrossRef
39.
C.U. Jorgensen, P. Homoe, M. Dahl, M.F. Hitz, Postoperative chronic hypoparathyroidism and quality of life after total thyroidectomy. JBMR 5(4), e10479 (2021)
40.
G. Kontogeorgos, Z. Mamasoula, E. Krantz, P. Trimpou, K. Landin-Wilhelmsen, C.M. Laine, Low health-related quality of life in hypoparathyroidism and need for PTH analog. Endocr. Connect. 11(1), e210379 (2022)PubMedCrossRef
41.
L. Mazoni, A. Matrone, M. Apicella, F. Saponaro, S. Borsari, E. Pardi, B. Cosci, I. Biagioni, P. Rossi, F. Pacciardi, A. Scionti, R. Elisei, C. Marcocci, F. Cetani, Renal complications and quality of life in postsurgical hypoparathyroidism: a case-control study. J. Endocrinol. Invest 45(3), 573–582 (2022)PubMedCrossRef
42.
T. Sikjaer, E. Moser, L. Rolighed, L. Underbjerg, L.S. Bislev, L. Mosekilde, L. Rejnmark, Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J. Bone Min. Res. 31(7), 1440–1448 (2016)CrossRef
43.
A. Song, S. Chen, Y. Yang, Y. Jiang, Y. Jiang, M. Li, W. Xia, O. Wang, X. Xing, PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism. J. Endocrinol. Invest 46(12), 2471–2479 (2023)PubMedCrossRef
44.
J.E. Ware Jr, C.D. Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6), 473–483 (1992)PubMedCrossRef
45.
C.W. Topp, S.D. Ostergaard, S. Sondergaard, P. Bech, The WHO-5 Well-Being Index: a systematic review of the literature. Psychother. Psychosom. 84(3), 167–176 (2015)PubMedCrossRef
46.
L.R. Derogatis, R.S. Lipman, L. Covi, SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol. Bull. 9(1), 13–28 (1973)PubMed
47.
D. von Zerssen, [Self-rating scales for evaluation of patient’s subjective state in cross-sectional and longitudinal studies of psychopathology (author’s transl)]. Arch. Psychiatr. Nervenkr (1970). 217(3), 299–314 (1973)CrossRef
48.
E. Brahler, J. Schumacher, C. Brahler, [First all-Germany standardization of the brief form of the Gissen Complaints Questionnaire GBB-24]. Psychother Psychosom. Med. Psychol. 50(1), 14–21 (2000).PubMed
49.
N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N.J. Duez, A. Filiberti, H. Flechtner, S.B. Fleishman, J.C. de Haes et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365–376 (1993)PubMedCrossRef
50.
M. Brod, L. McLeod, D. Markova, J. Gianettoni, S. Mourya, Z. Lin, A. Shu, A. Smith, Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES). J. Patient Rep. Outcomes 5(1), 70 (2021)PubMedPubMedCentralCrossRef
51.
S. Singer, A. Al-Ibraheem, M. Pinto, I. Iakovou, A.A. Osthus, E. Hammerlid, L.D. Locati, E. Gamper, J. Ignacio, S.J. Jordan, N. Kiyota, M. Buettner, D. Engesser, R. Canotilho, G. Ioannidis, O. Husson, R.R. Gama, G. Fanetti, L. Moss, J. Inhestern, G. Andry, D. Fuehrer, D. Kulis, H. Rimmele, G. Sykiotis, International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34. Thyroid 33(9), 1078–1089 (2023)PubMed
52.
T. Harslof, L. Rolighed, L. Rejnmark, Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic review. Endocrine 64(1), 176–183 (2019)PubMedCrossRef
53.
H.M. Mehanna, A. Jain, H. Randeva, J. Watkinson, A. Shaha, Postoperative hypocalcemia-the difference a definition makes. Head. Neck. 32(3), 279–283 (2010)PubMedCrossRef
54.
G. Erez, L. Selman, F.E. Murtagh, Measuring health-related quality of life in patients with conservatively managed stage 5 chronic kidney disease: limitations of the Medical Outcomes Study Short Form 36: SF-36. Qual. Life Res. 25(11), 2799–2809 (2016)PubMedPubMedCentralCrossRef
55.
J.P. Hobson, R.J. Meara, Is the SF-36 health survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson’s disease? Qual. Life Res. 6(3), 213–216 (1997)PubMedCrossRef
56.
M. Buttner, D. Krogh, H. Siggelkow, S. Singer, What are predictors of impaired quality of life in patients with hypoparathyroidism? Clin. Endocrinol. (Oxf.) 97(3), 268–275 (2022)PubMedCrossRef
57.
J.E. KM Ware, J. Bjoermer, D.M. Turner-Bowker, B. Gandek, M. Maruish, SF-36v2 Health survey standard form disease-specific norms, 2nd edn. (Quality Metric Inc, 2007)
58.
K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.) 56(5), 581–588 (2002)PubMedCrossRef
59.
I. Nermoen, E.S. Husebye, J. Svartberg, K. Lovas, Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. Eur. J. Endocrinol. 163(3), 453–459 (2010)PubMedCrossRef
60.
A.G. Bago, E. Dimitrov, R. Saunders, L. Seress, M. Palkovits, T.B. Usdin, A. Dobolyi, Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162(1), 128–147 (2009)PubMedCrossRef
61.
S. Balabanov, U. Tollner, H.P. Richter, F. Pohlandt, G. Gaedicke, W.M. Teller, Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol. (Copenh) 106(2), 227–233 (1984)PubMed
62.
P. Divieti, N. Inomata, K. Chapin, R. Singh, H. Juppner, F.R. Bringhurst, Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 142(2), 916–925 (2001)PubMedCrossRef
63.
B. Gellen, D. Zelena, T.B. Usdin, A. Dobolyi, The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice. Physiol. Behav. 181, 51–58 (2017)PubMedCrossRef
64.
T.B. Usdin, T.I. Bonner, S.R. Hoare, The parathyroid hormone 2 (PTH2) receptor. Recept Channels 8(3-4), 211–218 (2002)PubMedCrossRef
65.
M. Buttner, D. Krogh, D. Fuhrer, C.T. Fuss, H.S. Willenberg, M. Luster, S. Singer, H. Siggelkow, Hypoparathyroidism—management, information needs, and impact on daily living from the patients’ perspective: results from a population-based survey. Hormones (Athens) 22(3), 467–476 (2023)PubMedCrossRef
66.
N.L. Cho, J. Moalem, L. Chen, C.C. Lubitz, F.D. Moore Jr, D.T. Ruan, Surgeons and patients disagree on the potential consequences from hypoparathyroidism. Endocr. Pract. 20(5), 427–446 (2014)PubMedCrossRef
67.
S.H. Kim, Y. Rhee, Y.M. Kim, Y.J. Won, J. Noh, H. Moon, J. Lee, S.G. Kim, Prevalence and complications of nonsurgical hypoparathyroidism in Korea: A nationwide cohort study. PLoS One 15(5), e0232842 (2020)PubMedPubMedCentralCrossRef
68.
G. Leidig-Bruckner, T. Bruckner, F. Raue, K. Frank-Raue, Long-term follow-up and treatment of postoperative permanent hypoparathyroidism in patients with medullary thyroid carcinoma: differences in complete and partial disease. Horm. Metab. Res. 48(12), 806–813 (2016)PubMedCrossRef
69.
L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J. Bone Min. Res. 29(11), 2504–2510 (2014)CrossRef
70.
D. Riedl, R. Gastl, E. Gamper, C.R. Arnold, D. Dejaco, F. Schoellmann, G. Rumpold, Cancer patients’ wish for psychological support during outpatient radiation therapy: Findings from a psychooncological monitoring program in clinical routine. Strahlenther. Onkol. 194(7), 655–663 (2018)PubMedPubMedCentralCrossRef
71.
72.
I. Anaforoglu, S. Sancak, E.M. Akbas, G.G. Oruk, M. Canat, K.A. Tezcan, Z.A. Uc, S. Gorar, G.C. Duman, G.F. Yaylali, M. Yilmaz, B.E. Bilir, H. Bozoglan, G. Akbaba, M.M. Tuna, S. Akcay, D. Tuzun, G.S. Bagir, F.E. Haydardedeoglu, G. Elbuken, G. Yorulmaz, O. Celik, M. Topbas, Effects of treatment adherence on quality of life in hypoparathyroid patients. Exp. Clin. Endocrinol. Diabetes 129(12), 918–925 (2021)PubMedCrossRef
73.
M.C. Astor, W. Zhu, S. Bjornsdottir, J. Bollerslev, O. Kampe, E.S. Husebye, Is there a need for an emergency card in hypoparathyroidism? J. Intern Med. 285(4), 429–435 (2019)PubMedCrossRef
74.
K. David, C. Moyson, D. Vanderschueren, B. Decallonne, Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 180(1), 71–78 (2019)PubMedCrossRef
75.
N.A.T. Hamdy, B. Decallonne, P. Evenepoel, D. Gruson, L. van Vlokhoven-Verhaegh, Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J. Endocrinol. Invest 44(7), 1437–1446 (2021)PubMedCrossRef
76.
A.A. Khan, H. AbuAlrob, Z. Punthakee, M. Shrayyef, R.E. Werfalli, H.A. Kassem, M. Braga, A. Millar, S. Hussain, S. Iqbal, T. Khan, T. Paul, S. Van Uum, J.E.M. Young, Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada. Endocrine 72(2), 553–561 (2021)PubMedCrossRef
77.
M.B. Zanchetta, D. Robbiani, B. Oliveri, E. Giacoia, A. Frigeri, S. Kallsbrum, H. Salerni, S. Lucas, A. Diaz, B. Perez, L. Pieroni, M.A. Arce Lange, S. Tormo, A. Kitaigrodsky, A.M. Galich, Hipopara-red, real life experience in 322 patients with hypoparathyroidism. J. Endocr. Soc. 5(2), bvaa181 (2021)PubMedCrossRef
78.
E.M. Wekking, B.C. Appelhof, E. Fliers, A.H. Schene, J. Huyser, J.G. Tijssen, W.M. Wiersinga, Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur. J. Endocrinol. 153(6), 747–753 (2005)PubMedCrossRef
Metadata
Title
Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review
Authors
Matthias Büttner
Susanne Singer
Katherine Taylor
Publication date
05-04-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03807-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits